{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:53:32Z","timestamp":1793796812694,"version":"4.6.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This was a multicentre case series supported by the European Crohn\u2019s and Colitis Organisation [ECCO] and performed as part of the Collaborative Network of Exceptionally Rare case reports [CONFER] project. The aim was to report on whether cutaneous lesions associated with inflammatory bowel disease [IBD] and refractory to standard medical therapy including anti-tumour necrosis factors [anti-TNFs], would respond to the newer biologic agents ustekinumab [UST] or vedolizumab [VDZ]. This report includes 28 patients with cutaneous lesions from 14 centres, all of whom had failed immunomodulator and anti-TNF therapy. Metastatic Crohn\u2019s disease [MCD] was diagnosed in 10 patients: UST led to remission in five cases and partial response in four cases, with a single report of VDZ inducing remission. All cases of MCD treated with UST responded after the first or second dose, and the median time for the five cases that attained remission was 5 months. Pyoderma gangrenosum [PG] was diagnosed in four cases: three of these attained remission with UST [median time to remission 4 months] and one case did not respond to VDZ. There were seven cases of erythema nodosum [EN]: UST led to remission in four cases and partial response in 1 case whilst VDZ had partial response in 2 cases and non-response in two cases. There were seven single cases of other inflammatory lesions. In summary, UST appears to be useful for different cutaneous lesions including MCD, PG, and EN, whereas VDZ does not appear to be useful for lesions that are independent of disease activity.<\/jats:p>","DOI":"10.1093\/ecco-jcc\/jjaa078","type":"journal-article","created":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T19:06:56Z","timestamp":1587236816000},"page":"1488-1493","source":"Crossref","is-referenced-by-count":47,"title":["Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series"],"prefix":"10.1093","volume":"14","author":[{"given":"Frank M","family":"Phillips","sequence":"first","affiliation":[{"name":"NIHR Nottingham Digestive Diseases Biomedical Research Centre, Nottingham University Hospitals, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-7093","authenticated-orcid":false,"given":"Bram","family":"Verstockt","sequence":"additional","affiliation":[{"name":"University Hospitals Leuven, Gastroenterology and Hepatology, KU Leuven, Chronic Diseases, Metabolism and Ageing, TARGID-IBD Unit, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Sebastian","sequence":"additional","affiliation":[{"name":"Hull and East Yorkshire Hospitals NHS Trust, Inflammatory Bowel Disease Unit, University of Hull and York, Hull York Medical School, Hull, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Ribaldone","sequence":"additional","affiliation":[{"name":"University of Turin, Surgical Sciences, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Vavricka","sequence":"additional","affiliation":[{"name":"University Hospital Zurich, Medicine, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Katsanos","sequence":"additional","affiliation":[{"name":"University of Ioannina School of Medical Sciences, Gastroenterology, Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin","family":"Slattery","sequence":"additional","affiliation":[{"name":"University Hospital Galway, Gastroenterology, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"de Suray","sequence":"additional","affiliation":[{"name":"Grand Hopital de Charleroi, Gastroenterology and Hepatology, Charleroi, Belgium University Hospital Saint-Luc, Gastroenterology and Hepatology, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Flores","sequence":"additional","affiliation":[{"name":"Hospital de Clinicas de Porto Alegre, Gastroenterology, Rio Grande do Sul, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Fries","sequence":"additional","affiliation":[{"name":"University Messina, Clinical Unit for Chronic Bowel Disorders, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Vincenzi","sequence":"additional","affiliation":[{"name":"University of Parma, Gastroenterology and Endoscopy Unit, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Capoferro","sequence":"additional","affiliation":[{"name":"University of Parma, Gastroenterology and Endoscopy Unit, Parma, Italy, Sacro Cuore Don Calabria of Negrar, Negrar, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Bachmann","sequence":"additional","affiliation":[{"name":"Siloah St. Trudpert Klinikum, Gastroenterology, Pforzheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Kopylov","sequence":"additional","affiliation":[{"name":"Sheba Medical Centre, Gastroenterology, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"key":"2020100505042400500_CIT0001","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2020100505042400500_CIT0002","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ecco-jcc\/jjx178","article-title":"Cutaneous morbidity among inflammatory bowel disease patients: a cohort study","volume":"12","author":"Vide","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2020100505042400500_CIT0003","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1136\/pgmj.2004.031633","article-title":"Important cutaneous manifestations of inflammatory bowel disease","volume":"81","author":"Trost","year":"2005","journal-title":"Postgrad Med J"},{"key":"2020100505042400500_CIT0004","doi-asserted-by":"crossref","first-page":"329","DOI":"10.5858\/arpa.2010-0666-RS","article-title":"Metastatic Crohn disease: a rare cutaneous entity","volume":"136","author":"Siroy","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"2020100505042400500_CIT0005","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"2020100505042400500_CIT0006","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2020100505042400500_CIT0007","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/ibd\/izy065","article-title":"Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease","volume":"24","author":"Dubinsky","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2020100505042400500_CIT0008","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/ecco-jcc\/jjz095","article-title":"Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: a systematic review","volume":"13","author":"Chateau","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2020100505042400500_CIT0009","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10620-018-4971-1","article-title":"Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease","volume":"63","author":"Fleisher","year":"2018","journal-title":"Dig Dis Sci"},{"key":"2020100505042400500_CIT0010","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/apt.14419","article-title":"Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort","volume":"47","author":"Tadbiri","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2020100505042400500_CIT0011","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/0016-5085(89)90649-5","article-title":"Healing of severe perineal and cutaneous Crohn\u2019s disease with hyperbaric oxygen","volume":"97","author":"Brady","year":"1989","journal-title":"Gastroenterology"},{"key":"2020100505042400500_CIT0012","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1046\/j.1440-1746.2001.02439.x","article-title":"Rapid response of severe refractory metastatic Crohn\u2019s disease to infliximab","volume":"16","author":"Miller","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"2020100505042400500_CIT0013","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1684\/ejd.2010.0975","article-title":"Cutaneous Crohn\u2019s disease presenting as genital warts: successful treatment with adalimumab","volume":"20","author":"Lestre","year":"2010","journal-title":"Eur J Dermatol"},{"key":"2020100505042400500_CIT0014","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/bjs.1800801235","article-title":"Surgical management of perineal and metastatic cutaneous Crohn\u2019s disease","volume":"80","author":"Williams","year":"1993","journal-title":"Br J Surg"},{"key":"2020100505042400500_CIT0015","doi-asserted-by":"crossref","DOI":"10.5070\/D32210032898","article-title":"Ustekinumab for the treatment of cutaneous Crohn\u2019s disease","author":"Abdat","year":"2016","journal-title":"Dermatol Online J"},{"key":"2020100505042400500_CIT0016","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1053\/j.gastro.2018.07.042","article-title":"Multiple unusual ulcerated skin lesions in a Crohn\u2019s disease patient","volume":"155","author":"Argyriou","year":"2018","journal-title":"Gastroenterology"},{"key":"2020100505042400500_CIT0017","first-page":"309","article-title":"The gut and the inflammatory bowel diseases inside-out: extra-intestinal manifestations","volume":"65","author":"Ribaldone","year":"2019","journal-title":"Minerva Gastroenterol Dietol"},{"key":"2020100505042400500_CIT0018","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"2020100505042400500_CIT0019","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ibd.20748","article-title":"Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn\u2019s disease","volume":"15","author":"Alkhouri","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"2020100505042400500_CIT0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/ajd.12744","article-title":"Treatment of severe recalcitrant pyoderma gangrenosum with ustekinumab","volume":"59","author":"Low","year":"2018","journal-title":"Australas J Dermatol"},{"key":"2020100505042400500_CIT0021","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/archdermatol.2011.168","article-title":"Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab","volume":"147","author":"Guenova","year":"2011","journal-title":"Arch Dermatol"},{"key":"2020100505042400500_CIT0022","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.3748\/wjg.14.2448","article-title":"Ulcerative colitis presenting as leukocytoclastic vasculitis of skin","volume":"14","author":"Akbulut","year":"2008","journal-title":"World J Gastroenterol"},{"key":"2020100505042400500_CIT0023","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1159\/000161562","article-title":"Leukocytoclastic vasculitis as an onset symptom of Crohn\u2019s disease","volume":"2","author":"Tsiamoulos","year":"2008","journal-title":"Case Rep Gastroenterol"},{"key":"2020100505042400500_CIT0024","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum","volume":"174","author":"Blok","year":"2016","journal-title":"Br J Dermatol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaa078\/33463034\/jjaa078.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/10\/1488\/33835559\/jjaa078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/10\/1488\/33835559\/jjaa078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T18:53:30Z","timestamp":1666378410000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/14\/10\/1488\/5823596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,22]]},"references-count":24,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,4,22]]},"published-print":{"date-parts":[[2020,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa078","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,4,22]]}}}